16:55:50 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaMERK Equities
SektorHälsovård
IndustriBioteknik
EXACT Therapeutics är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis tekniska plattformar för läkemedelstestning. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och mervärdesprodukter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Bolaget gick tidigare under namnet Phoenix Solutions och har idag sitt huvudkontor i Oslo.

Kalender

2021-08-25 Kvartalsrapport 2021-Q2
2021-06-01 Årsstämma 2021
2021-05-14 Ordinarie utdelning EXTX 0.00 NOK
2021-04-29 Bokslutskommuniké 2020
2020-07-27 Split EXTX 1:250
2020-07-24 Extra Bolagsstämma 2020
2021-06-07 10:02:54
Oslo, 7 June 2021: Reference is made to the stock exchange release by EXACT
Therapeutics AS ("EXACT-Tx" or the "Company") on 7 June 2021 regarding a share
capital increase in connection with the Company's restricted stock unit (RSU)
programme.

Masha Strømme, chair of EXACT-Tx, has through her majority owned company PAACS
Invest AS, subscribed for 6,489 shares at NOK 20.804 per share. Following this
transaction, Masha Strømme will hold 2,684,739 shares in EXACT-Tx through PAACS
Invest AS.

Sir William Castell, vice-chair of EXACT-Tx, has subscribed for 9,998 shares at
NOK 20.804 per share. Following this transaction, Sir William Castell will hold
342,498 shares in EXACT-Tx.

Hans Henrik Klouman, board member of EXACT-Tx, has subscribed for 2,900 shares
at NOK 20.804 per share. Following this transaction, Hans Henrik Klouman will
hold 402,650 shares in EXACT-Tx through Virkelyst AS.

Aitana Peire, board member of EXACT-Tx, has subscribed for 5,030 shares at NOK
20.804 per share. Following this transaction, Aitana Peire will hold 5030 shares
in EXACT-Tx.

About EXACT-Tx
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug
enhancement - with the potential to significantly amplify the clinical utility
of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and neurological conditions. www.exact-tx.com